Paragon 28 Revenue and Competitors

Denver, CO USA

Location

#2548

Growjo Ranking

Estimated Revenue & Valuation

  • Paragon 28's estimated annual revenue is currently $139.8M per year.(i)
  • Paragon 28's estimated revenue per employee is $153,067
  • Paragon 28's current valuation is $1.2B. (January 2022)

Employee Data

  • Paragon 28 has 913 Employees.(i)
  • Paragon 28 grew their employee count by 19% last year.

Paragon 28's People

NameTitleEmail/Phone
1
Chief Financial OfficerReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Human Resources OfficerReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
VP Patient SpecificReveal Email/Phone
6
VP Engineering, ArthroplastyReveal Email/Phone
7
VP International Finance & Global Shared ServicesReveal Email/Phone
8
Controller and Chief Accounting Officer (CAO)Reveal Email/Phone
9
EVP Marketing and Medical EducationReveal Email/Phone
10
VP National AccountsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.3M29-6%N/AN/A
#2
$5.3M21-28%N/AN/A
#3
$2.5M10-17%N/AN/A
#4
$11.5M465%N/AN/A
#5
$5.5M22-33%N/AN/A
#6
$10.8M430%N/AN/A
#7
$30.4M121-10%N/AN/A
#8
$61.5M2454%N/AN/A
#9
$3.3M13-13%N/AN/A
#10
$27.4M109N/AN/AN/A
Add Company

What Is Paragon 28?

Paragon 28 was established in 2010 as an orthopedic foot and ankle company. The name Paragon 28 was chosen to show that we are exclusively a foot and ankle company, with the 28 representing the number of bones in the foot. We will remain true to that vision. Paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. Our mission is to strategically build a company around the core principles that drive innovation and quality. Relentlessly working to advance the science behind foot and ankle surgery, Paragon 28 is passionate about and committed to: - Creation and Innovation: Blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - A Focus on Service: A customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - Efficient Practices: Meeting the needs of increasing pricing pressures and reimbursement while continuing to develop cutting-edge surgical implants. - Practical and Comprehensive Solutions: Creating complete surgeon-centric systems, specialty instruments, and next generation implants to solve real world issues faced by foot and ankle surgeons. - Research Motivated: Improving clinical outcomes through meaningful and unbiased research. We are ready to embrace research data regardless of marketing impact. Motivation, competition and the desire to learn are unique characteristics that are incredibly valuable to our success. Paragon 28's work environment is modern and exciting. We are seeking experienced and energetic individuals to join our team in areas of Quality, Engineering, Marketing, Sales, Administration and Accounting.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

N/A

Total Funding

913

Number of Employees

$139.8M

Revenue (est)

19%

Employee Growth %

$1.2B

Valuation

N/A

Accelerator

Paragon 28 News

2022-04-17 - Paragon 28 To Report First Quarter 2022 Financial Results on ...

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the...

2022-04-17 - Paragon 28 launches R3Act ankle stabilization system

Paragon 28 today launched its R3Act stabilization system for acute or chronic syndesmotic ankle injuries.

2022-03-22 - Paragon 28 Announces Appointment of Meghan Scanlon to ...

--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market,...

2021-05-20 - Paragon 28® Inc., Expands its Novel Biologics Portfolio with Addition of Three Families of DBM

ENGLWOOD, Colo., May 20, 2021 /PRNewswire/ -- Paragon 28 is pleased to announce the launch of the BEAST™ Injectable Putty, BEAST PLUS™, and BEAST™ Osteobiologic Sponge (BOB™)! All three grafts have a high osteoinductive potential, excellent handling characteristics, and are processed using a ...

2020-08-17 - Paragon 28 Completes Series B Financing

Paragon 28, Inc., an Englewood, Colo.-based orthopedic foot and ankle company, completed a Series B financing of undisclosed amount. The round was co-led by Piper Sandler Merchant Banking, a commercial stage growth equity investment business of Piper Sandler Companies, and MVM Partners, a healt ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$398.4M10546%N/A
#2
$412.8M12995%N/A
#3
$336.4M165726%N/A
#4
$822.2M2175-2%N/A
#5
$652.8M3216N/AN/A